

Drugs@FDA: FDA-Approved Drugs

 [SHARE \(HTTPS://WWW.FACEBOOK.COM/SHARER/SHARER.PHP?U=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/DAF/INDEX.CFM?EVENT=BASICSEARCH.PROCESS\)](https://www.facebook.com/sharer/sharer.php?u=https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.Process)

 [TWEET \(HTTPS://TWITTER.COM/INTENT/TWEET/?TEXT=DRUGS@FDA: FDA-APPROVED DRUGS&URL=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/DAF/INDEX.CFM?EVENT=BASICSEARCH.PROCESS\)](https://twitter.com/intent/tweet/?text=Drugs@FDA: FDA-Approved Drugs&url=https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.Process)

 [LINKEDIN \(HTTPS://WWW.LINKEDIN.COM/SHAREARTICLE?MINI=TRUE&URL=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/DAF/INDEX.CFM?EVENT=BASICSEARCH.PROCESS&TITLE=DRUGS@FDA: FDA-APPROVED DRUGS&SOURCE=FDA\)](https://www.linkedin.com/sharearticle?mini=true&url=https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.Process&title=Drugs@FDA: FDA-Approved Drugs&source=fda)

 [PIN IT \(HTTPS://WWW.PINTEREST.COM/PIN/CREATE/BUTTON/?URL=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/DAF/INDEX.CFM?EVENT=BASICSEARCH.PROCESS&DESCRIPTION=DRUGS@FDA: FDA-APPROVED DRUGS\)](https://www.pinterest.com/pin/create/button/?url=https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.Process&description=Drugs@FDA: FDA-Approved Drugs)

 [EMAIL \(MAILTO:?SUBJECT=DRUGS@FDA: FDA-APPROVED DRUGS&BODY=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/DAF/INDEX.CFM?EVENT=BASICSEARCH.PROCESS\)](mailto:?subject=Drugs@FDA: FDA-Approved Drugs&body=https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.Process)

 PRINT

[Home \(index.cfm\)](#) | [Previous Page](#)

New Drug Application (NDA): 203975

Company: GLAXOSMITHKLINE

 [EMAIL \(MAILTO:?SUBJECT=DRUGS@FDA: FDA APPROVED DRUG PRODUCTS&BODY=HTTP://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/DAF/INDEX.CFM?EVENT=OVERVIEW.PROCESS%26VARAPPLNO=203975\)](mailto:?subject=Drugs@FDA: FDA APPROVED DRUG PRODUCTS&body=http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=Overview.Process%26VARAPPLNO=203975)

- [Summary Review \(http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203975Orig1s000SumR.pdf\)](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203975Orig1s000SumR.pdf)

[Products on NDA 203975](#)



CSV

Excel

Print

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
ANORO ELLIPTA	UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE	EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH	POWDER;INHALATION	Prescription	None	Yes	Yes

Showing 1 to 1 of 1 entries

Approval Date(s) and History, Letters, Labels, Reviews for NDA 203975**Original Approvals or Tentative Approvals**

CSV	Excel	Print			
Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert
12/18/2013	ORIG-1	Approval	Type 1 - New Molecular Entity and Type 4 - New Combination	STANDARD	Label (PDF) (https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/) Letter (PDF) (https://www.accessdata.fda.gov/drugsatfda_docs/applletter/2013/) Review (https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203975Orig1s1.pdf) Summary Review (PDF) (https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203975Orig1s1.pdf)

Showing 1 to 1 of 1 entries

Supplements

CSV	Excel	Print
-----	-------	-------

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert
06/06/2019	SUPPL-10	Efficacy-Labeling Change With Clinical Data	Label (PDF) (https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/203975Orig1s010lbl.pdf) Letter (PDF) (https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/203975Orig1s010_REPLACEMENTltr.pdf)
05/29/2019	SUPPL-9	Labeling- Package Insert	Label (PDF) (https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/203975s009lbl.pdf) Letter (PDF) (https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/203975Orig1s009ltr.pdf)
10/17/2017	SUPPL-7	Labeling- Package Insert, Labeling- Medication Guide	Label (PDF) (https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203975s007lbl.pdf) Letter (PDF) (https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/203975Orig1s007ltr.pdf)
03/22/2017	SUPPL-5	Labeling- Medication Guide, Labeling- Package Insert	Label (PDF) (https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203975s005lbl.pdf) Letter (PDF) (https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/203975Orig1s005ltr.pdf)
02/24/2016	SUPPL-3	Labeling- Medication Guide	Label (PDF) (https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203975s003lbl.pdf) Letter (PDF) (https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/203975Orig1s003ltr.pdf)
08/27/2015	SUPPL-2	Manufacturing (CMC)	

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert
08/07/2015	SUPPL-1	Manufacturing (CMC)	

Showing 1 to 7 of 7 entries

Labels for NDA 203975





NDA 203975

NDA APPROVAL

GlaxoSmithKline
Five Moore Drive
Research Triangle Park, NC 27709

Attention: Mary V. Sides
Director, Global Regulatory Affairs

Dear Ms. Sides:

Please refer to your New Drug Application (NDA) dated and received December 18, 2012, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Anoro Ellipta (umeclidinium /vilanterol powder for inhalation), 62.5 mcg/ 25 mcg.

We acknowledge receipt of your amendments dated December 19, 2012, and February 1, 8 (2), 15, and 22, March 19 and 25 (3), April 12 and 26, May 8, 16, 20, and 31(2), June 7 and 11, August 1, 14 (2), and 16, September 6 and 25, October 3, 4, 18, and 28, November 15 and 18 (2), and December 10, 11, 12, and 13, 2013.

This new drug application provides for the use of Anoro Ellipta (umeclidinium /vilanterol powder for inhalation) for the long-term, once daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert and Medication Guide). Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*, available at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

CARTON AND IMMEDIATE CONTAINER LABELS

Submit final printed carton and immediate container labels that are identical to the carton and immediate container labels submitted on December 10, 2013, as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008)*. Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission “**Final Printed Carton and Container Labels for approved NDA 203975.**” Approval of this submission by FDA is not required before the labeling is used.

Marketing the product(s) with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric study requirement for this application because studies would be impossible or highly impracticable since the disease does not exist in pediatric patients.

EXPIRATION DATING PERIOD

A 24-month expiration dating period is granted for Anoro Ellipta when stored at room temperature between 68°F and 77°F (20°C and 25°C); excursions permitted from 59° to 86°F (15° to 30°C).

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert to:

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion
5901-B Ammendale Road
Beltsville, MD 20705-1266

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the package insert, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at

<http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>.

Information and Instructions for completing the form can be found at

<http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

METHODS VALIDATION

We have not completed validation of the regulatory methods. However, we expect your continued cooperation to resolve any problems that may be identified.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

MEDWATCH-TO-MANUFACTURER PROGRAM

The MedWatch-to-Manufacturer Program provides manufacturers with copies of serious adverse event reports that are received directly by the FDA. New molecular entities and important new biologics qualify for inclusion for three years after approval. Your firm is eligible to receive copies of reports for this product. To participate in the program, please see the enrollment instructions and program description details at

<http://www.fda.gov/Safety/MedWatch/HowToReport/ucm166910.htm>.

POST APPROVAL FEEDBACK MEETING

New molecular entities and new biologics qualify for a post approval feedback meeting. Such meetings are used to discuss the quality of the application and to evaluate the communication process during drug development and marketing application review. The purpose is to learn from successful aspects of the review process and to identify areas that could benefit from improvement. If you would like to have such a meeting with us, call the Regulatory Project Manager for this application.

PDUFA V APPLICANT INTERVIEW

FDA has contracted with Eastern Research Group, Inc. (ERG) to conduct an independent interim and final assessment of the Program for Enhanced Review Transparency and Communication for NME NDAs and Original BLAs under PDUFA V ('the Program'). The PDUFA V Commitment Letter states that these assessments will include interviews with applicants following FDA action on applications reviewed in the Program. For this purpose, first-cycle actions include approvals, complete responses, and withdrawals after filing. The purpose of the interview is to better understand applicant experiences with the Program and its ability to improve transparency and communication during FDA review.

ERG will contact you to schedule a PDUFA V applicant interview and provide specifics about the interview process. Your responses during the interview will be confidential with respect to the FDA review team. ERG has signed a non-disclosure agreement and will not disclose any identifying information to anyone outside their project team. They will report only anonymized results and findings in the interim and final assessments. Members of the FDA review team will be interviewed by ERG separately. While your participation in the interview is voluntary, your feedback will be helpful to these assessments.

If you have any questions, call Leila P. Hann, Regulatory Project Manager, at (301) 796-3367.

Sincerely,

{See appended electronic signature page}

Curtis J. Rosebraugh, M.D., M.P.H.
Director
Office of Drug Evaluation II
Office of New Drugs
Center for Drug Evaluation and Research

Enclosures:
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

CURTIS J ROSEBRAUGH
12/18/2013